* Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected
to show a fall in quarterly revenue when it reports results on
May 4 (estimated).
* Refinitiv's mean analyst estimate for Adverum
Biotechnologies
Inc is for a loss of 31 cents per share. For the same quarter
last year, the company reported a loss of 29 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 4.6%
in the last three months.
* Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $4, above its last closing price
of $1.07.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.34 -0.35 Missed -1.9
Sep. 30 2021 -0.31 -0.37 -0.39 Missed -4
Jun. 30 2021 -0.36 -0.39 -0.45 Missed -15.7
Mar. 31 2021 -0.38 -0.38 -0.29 Beat 23.9
Dec. -0.31 -0.32 -0.39 Missed -20.7
31 2020
Sep. 30 2020 -0.35 -0.34 -0.31 Beat 9.7
Jun. 30 2020 -0.28 -0.28 -0.36 Missed -27.1
Mar. 31 2020 -0.27 -0.27 -0.31 Missed -13.1
This summary was machine generated May 2 at 11:01 GMT. All
figures in US dollars unless otherwise stated